Here is a list of some of the randomized controlled trials in humans that showed reversal of plaque using statins:
(PAV stands for Percent Atheroma Volume.)
The SATURN trial (Nicholls et al., 2011) showed high-dose atorvastatin (80mg) regressed PAV by -0.99% compared to -0.31% with low-dose atorvastatin (10mg) over 24 months in 1039 patients (p=0.001).
The REVERSAL trial (Nissen et al., 2004) found high-dose atorvastatin (80mg) halted progression of PAV (0.4% increase) compared to low-dose pravastatin (40mg; +2.7% increase) over 18 months in 502 patients (p=0.02).
The ASTEROID trial (Nissen et al., 2006) showed high-dose rosuvastatin (40mg) regressed PAV by -0.98% compared to baseline over 24 months in 507 patients (p<0.001).
The COSMOS trial (Puri et al., 2016) found rosuvastatin (40mg) + canakinumab (anti-inflammatory) regressed PAV by -0.95% compared to -0.05% with placebo over 52 weeks in 418 patients (p<0.001).
The PROSPECT trial (Stone et al., 2011) showed patients on statins had a lower rate of plaque progression (24.6%) compared to those not on statins (38.5%) over 3.4 years (p=0.008).
The JAPAN-ACS trial (Hiro et al., 2009) found strong statins reduced plaque volume by -5.1% compared to -0.7% with non-statin therapy over 8-12 months in 252 patients (p=0.015).
Gokhan Can collected more data on plaque reversal for other interventions as well in this blog post: mylongevityjourney.blogspot.com/2023/12/plaque-reduction-cvd.html



